http://www.biospace.comBioSpace RSS GeneratorSat, 25 May 2013 06:34:07 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.biospace.com/news_story.aspx?StoryID=297893&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Merck Provides Update on Phase III Clinical Program for Preladenant, the Company's Investigational Parkinson's Disease Medicine</font></b><br><br>WHITEHOUSE STATION, N.J.--(BUSINESS WIRE...Fri, 24 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297331&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility</font></b><br><br>NEW YORK--(BUSINESS WIRE)-...Wed, 22 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296187&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><b>Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma</b><br><br>INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced...Wed, 15 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130508005364&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>CytRx Provides Update on Clinical Programs </font></b><br><br>LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing...Fri, 10 May 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/121896/bayer-drops-hemophilia-candidate-bay-86-6150-on-safety-concerns.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.<br><br>Help employers...Tue, 07 May 2013 12:00:00 AM GMThttp://www.bloomberg.com/news/2013-04-18/celltrion-drops-late-stage-trial-of-roche-rituxan-drug-copy.htmlCelltrion Inc. (068270) dropped a late-stage trial of a biosimilar version of Roche Holding AG (ROG)s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis (NOVN) AG. Celltrion had planned to take its drug, CT-P10, into phase- III trials later this year, Asthika Goonewardene, a London-based analyst for Bloomberg Industries, wrote in a note today...Fri, 19 Apr 2013 12:00:00 AM GMThttp://www.medpagetoday.com/HematologyOncology/SkinCancer/38241Unexpected liver toxicity derailed a phase I melanoma trial of concurrent treatment with the first two targeted agents approved for the disease, according to a brief communication from investigators. Four of the first six patients treated with vemurafenib (Zelboraf) and ipilimumab (Yervoy) developed grade 2 or 3 elevations of aminotransferase (ALT), as did three of the first four patients in a second...Thu, 04 Apr 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/121094/clavis-pharma-stops-elacytarabine-development-on-negative-ph-iii-trial-in-acute-myeloid-leukemia.htmlClavis Pharma ASA (CLAVIS), a Norwegian biotech, is considering closing or selling itself to another company after its experimental leukemia treatment elacytarabine failed in a late-stage trial. Clavis has a short-list of Scandinavian private companies that may be interested in taking it over and will approach them over the next few weeks, Chief Executive Officer Olav Helleboe said on a conference...Wed, 03 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291535&full=1NEW YORK, March 26, Mar 26, 2013 (GLOBE NEWSWIRE via COMTEX) -- Restructuring to Place Exclusive Strategic Focus on Synthetic Biology Programs</p><p>Company to Host Conference Call Today, March 26, 2013 at 8:30 AM ET</p><p>ZIOPHARM Oncology, Inc. ZIOP -61.99% , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that its Phase...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291057&full=1JERUSALEM--(BUSINESS WIRE)-- BioLineRx (BLRX) (BLRX.TA), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, indicate that the trial would not meet the pre-specified primary efficacy endpoint. After conferring...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.pmlive.com/pharma_news/pfizer_drops_hepatitis_c_candidate_filibuvir_466696Pfizer Inc. (PFE) has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease. The New York-based drug giant decided to discontinue development of PF-00868554, also known as filibuvir, following a strategic review, said spokeswoman Victoria Davis. She said the decision wasn...Tue, 19 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290101&full=1 <div class"xn-content"><p><span class"xn-location">QUEBEC CITY</span>, <span class"xn-chron">March 11, 2013</span> /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130311005504&newsLang=enSTOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (STO:MOB) has decided to discontinue the development of Limtop - a drug candidate for the treatment of actinic keratosis. The decision is based on data from a completed phase II clinical trial, where the efficacy of Limtop did not reach the predefined target. "Based on data from the completed study, we deem that the project's commercial potential...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.washingtonpost.com/politics/fda-halts-pediatric-studies-of-amgen-thyroid-drug-after-14-year-old-patient-dies/2013/02/26/3d737176-804e-11e2-a671-0307392de8de_story.htmlThe Food and Drug Administration said on Tuesday it has stopped all pediatric clinical trials of Amgen Inc's Sensipar after the death of a 14-year-old patient taking part in a study of the drug. Sensipar, which is approved for adults, is used to lower dangerously high calcium levels in the blood. The agency said it was collecting information on the circumstances of the teenager's death. It said it...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287386&full=1Brussels (Belgium), 11 February 2013 - 7:00 AM (CET) regulated information - UCB and its partner, Amgen Inc., have decided to not pursue a phase 3 clinical trial program for CDP7851/AMG785 (romosozumab) in acceleration of fracture healing based on the evaluation of currently available Phase 2 results from accelerated fracture healing studies and general regulatory guidance on fracture healing programs...Wed, 13 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=286960&full=1INDIANAPOLIS</span>, <span class"xn-chron">Feb. 7, 2013</span> /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, due to lack of efficacy. The decision was not based on safety concerns. The tabalumab Phase 3 program for systemic lupus erythematosus...Fri, 08 Feb 2013 12:00:00 AM GMThttp://www.bloomberg.com/news/2013-02-04/idenix-stops-development-of-two-hepatitic-c-treatments.html?cmpid=yhooIdenix Pharmaceuticals Inc. (IDIX) is shelving the development of two hepatitis C therapies that had been stopped by U.S. regulators after a competing therapy was linked to heart risks. The Food and Drug Administration put a hold on studies of the companys nucleotide polymerase inhibitors IDX184 and IDX19368, after safety issues arose while Bristol-Myers Squibb Co. (BMY) tested a hepatitis C therapy...Wed, 06 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=286242&full=1WASHINGTON</span>, <span class"xn-chron">Jan. 31, 2013</span> /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD. The clinical study did not meet the primary endpoint of...Fri, 01 Feb 2013 12:00:00 AM GMThttp://www.forbes.com/sites/matthewherper/2013/01/11/what-merck-told-doctors-about-tredaptive-before-it-stopped-selling-it/This morning, Merck announced that it would suspend sales of Tredaptive, the heart drug that combines the B vitamin niacin with a new medicine, laropiprant, that prevents niacins main side effect, hot, unpleasant, facial flushing. This comes just weeks after a big trial of Tredaptive not only found that the drug did not prevent heart attacks, strokes, and heart procedures as was expected bu that it...Tue, 15 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284525&full=1WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYS: MRK) , known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE (extended-release niacin/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States.</p><p>Merck is taking these steps based on the current understanding of the preliminary...Mon, 14 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282456&full=1RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy. The decision followed a planned interim futility analysis, which examined patients...Tue, 18 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282208&full=1Ingelheim, Germany, 11 December 2012 Boehringer Ingelheim has taken the voluntary decision to discontinue treatment with the oral anticoagulant dabigatran etexilate in a phase II clinical trial in patients with artificial heart valves. The company based its decision on interim results from the phase II RE-ALIGNTM trial which suggested that the investigated dosing regimen did not achieve the desired...Thu, 13 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281190&full=1MENLO PARK, Calif., December 3, 2012 - Geron Corporation (Nasdaq: GERN) today announced that the company has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres...Mon, 10 Dec 2012 12:00:00 AM GMThttp://www.pmlive.com/pharma_news/bms_ends_development_of_alzheimers_candidate_avagacestat_452851Bristol-Myers Squibb Co. (BMY) ended development of an experimental Alzheimers disease treatment after the drug was shown not to be effective, the company said. The drug, avagacestat, was in the second of three phases of clinical development needed for U.S. regulatory approval. Bristol-Myers, based in New York, said data from a completed trial of the drug and a current study showed the therapy wasn...Wed, 05 Dec 2012 12:00:00 AM GMThttp://www.thestreet.com/story/11780088/1/ranbaxy-halts-production-of-generic-lipitor-hot-trends.htmlRanbaxy Laboratories Ltd. has stopped production of its generic version of cholesterol-lowering drug Lipitor as the company investigates what caused tiny glass particles to appear in some bottles, triggering a large recall earlier this month. Details also emerged Thursday of a smaller recall of Ranbaxy's generic Lipitor in August, over a potential pill mix-up. The U.S. Food and Drug Administration...Mon, 03 Dec 2012 12:00:00 AM GMThttp://online.wsj.com/article/SB10001424127887323551004578116852282793018.htmlMerck MRK 0.09% & Co. halted development of a pill combining its diabetes drug Januvia with a generic version of the widely used cholesterol fighter Lipitor, citing unspecified business reasons. The Whitehouse Station, N.J., company discontinued development of MK-0431E, which Merck had previously planned to submit for regulatory approval in 2014. Merck spokeswoman Pam Eisele said Tuesday the decision...Wed, 14 Nov 2012 12:00:00 AM GMThttp://www.healio.com/cardiology/chd-prevention/news/online/%7B1E0CA070-F85D-4CEB-9AF9-2B1D61098BF5%7D/Dalcetrapib-increased-HDL-did-not-reduce-risk-for-CV-eventsRoche Holding AG (ROG)s abandoned heart drug dalcetrapib, designed to raise levels of good cholesterol, also boosted blood pressure and inflammation, researchers said. Dalcetrapib marks the second failure in what was expected to be a new blockbuster class of heart medicines known as CETP inhibitors. The Basel, Switzerland-based drugmaker halted development of the drug in May, saying an early look...Wed, 07 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=278234&full=1BELLEVILLE, ON</span>, <span class"xn-chron">Nov. 5, 2012</span> /PRNewswire/ -<b></b>Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with <i>Urocidin </i>in non-muscle-invasive bladder cancer is being discontinued.<br />The trial, a randomized, active-controlled...Mon, 05 Nov 2012 12:00:00 AM GMThttp://www.newscientist.com/article/mg21628883.700-pioneering-geron-stem-cell-work-may-get-back-on-track.htmlThe world's largest embryonic stem cell research programme could be given a new lease of life. In 2011, biotech giant Geron announced that it was closing its stem cell programme, even though it had conducted a decade of research and treated four people in the first clinical trial of human embryonic stem cells (hESCs). Now, Geron's former chief executive Thomas Okarma, and founder Michael West, have...Mon, 29 Oct 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/10/18/abbott-kidneydrug-idUSL3E8LI5IY20121018Oct 18 (Reuters) - Abbott Laboratories Inc said its partner Reata Pharmaceuticals was discontinuing a late-stage trial of their potential blockbuster treatment for chronic kidney disease and diabetes based on safety concerns raised by an independent safety committee.<br><br>The news for bardoxolone represents a major setback for Abbott just months before the planned Jan. 1 spinoff of its branded...Mon, 22 Oct 2012 12:00:00 AM GMThttp://www.bizjournals.com/washington/news/2012/10/11/novartis-drops-long-acting-version-of.html?ana=otjrssWashington Business Journal by Bill Flook, Staff Reporter </p><p>Novartis Pharma AG is discontinuing development on a long-acting injectable version of Vanda Pharmaceuticals Inc.s Fanapt, the District-based biotech reported in a securities filing.</p><p>Novartis has marketed Fanapt, a schizophrenia drug and Vandas lead product, since 2010. The pharma giant has exclusive rights to develop...Fri, 12 Oct 2012 12:00:00 AM GMTOxford, UK 10 October 2012: Oxford BioMedica (Oxford BioMedica or the Company) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it plans to close the Phase II study in the United States (US) to assess the activity of TroVax (MVA-5T4) in patients with progressive hormone refractory prostate cancer (HRPC). TroVax continues to have an active Phase II development...Thu, 11 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275195&full=1PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development of GSK2251052. As previously disclosed, GSK halted the most recent clinical trials of GSK2251052 due to the identification of microbiological findings of resistance in a small number of patients in the Phase 2b trial for...Mon, 08 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274704&full=1WOBURN, Mass. & TOKYO--(BUSINESS WIRE)-- ArQule, Inc. (ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 MARQUEE (Met inhibitor ARQ 197 plus Erlotinib vs Erlotinib plus placebo in NSCLC) trial recommended the study be stopped early following a planned interim analysis, when they concluded that the study would not meet...Wed, 03 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274468&full=1September 28, 2012 - Novo Nordisk today announced the decision to discontinue the development ofvatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase 3a trial adeptTM 2. On 9 August, Novo Nordisk announced that a few patients in the trial had developed anti-drug antibodies to vatreptacog...Tue, 02 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273989&full=1CAMBRIDGE, Mass., Sep 25, 2012 (BUSINESS WIRE) -- --- ALS-2200: Data from additional cohort of seven-day viral kinetic study with ALS-2200 (200 mg, QD) in combination with ribavirin show median 4.18 log10 reduction in HCV RNA with 5 of 8 people below the limit of quantification; treatment was well-tolerated -</p><p>Vertex Pharmaceuticals Incorporated VRTX -1.67% and its collaborator Alios BioPharma...Wed, 26 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273738&full=1DUBLIN, Calif., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that clinical development of amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor that inhibits the mutant forms of c-Kit and PDGFR alpha and disrupts DNA repair likely through...Mon, 24 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273097&full=1WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept, Inc. (TRGT) today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV...Tue, 18 Sep 2012 12:00:00 AM GMThttp://online.wsj.com/article/BT-CO-20120913-711861.html?mod=WSJ_qtoverview_wsjlatestJohnson & Johnson (JNJ) terminated a clinical trial of an experimental drug for a skin disorder after two patients in Japan experienced serious drops in infection-fighting white blood cells.Mon, 17 Sep 2012 12:00:00 AM GMThttp://www.nasdaq.com/article/lundbeck-to-halt-sale-of-leukemia-drug-citing-supply-problems-20120913-00984H. Lundbeck A/S (LUN.KO) plans to stop selling a leukemia treatment because of manufacturing and supply difficulties. Denmark-based Lundbeck "is no longer in a position to guarantee a future supply" of the drug Elspar, Roger Keding, vice president of supply chain management, said in an Aug. 3 letter to U.S. health-care providers. "Lundbeck has concluded that continuing to manufacture and distribute...Mon, 17 Sep 2012 12:00:00 AM GMThttp://www.thestreet.com/story/11692655/1/geron-stung-by-cancer-drug-blowup.html?cm_ven=GOOGLEN(Thomson Reuters ONE via COMTEX) -- Based on an unplanned interim analysis, Geron Corporation GERN -46.90% announced Monday morning that it will be discontinuing a Phase II study of its developmental drug Imetelstat against metastatic HER2-negative breast cancer. In the study, patients receiving the treatment along with paclitaxel had a lower Progression Free Survival (PFS) than patients receiving...Tue, 11 Sep 2012 12:00:00 AM GMThttp://www.rttnews.com/1962367/zalicus-to-halt-further-clinical-development-with-synavive-quick-facts.aspx?type=qfCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zalicus Inc. (ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis (RA).</p><p>The Phase 2b trial demonstrated that patients...Mon, 10 Sep 2012 12:00:00 AM GMThttp://www.rttnews.com/1961429/palatin-says-partner-astrazeneca-to-stop-further-azd2820-drug-development.aspx?type=bn&utm_source=google&utm_campaign=sitemapCRANBURY, N.J.</span>, <span class"xn-chron">Sept. 7, 2012</span> /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration...Mon, 10 Sep 2012 12:00:00 AM GMThttp://www.zacks.com/stock/news/81844/lillys-alzheimers-candidate-failsINDIANAPOLIS</span>, <span class"xn-chron">Aug. 29, 2012</span> /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia. The decision was made after a recently conducted independent futility analysis concluded HBBN, the second...Thu, 30 Aug 2012 12:00:00 AM GMThttp://www.nytimes.com/2012/08/24/business/bristol-myers-ends-work-on-hepatitis-c-drug.htmlBristol-Myers Squibb said Thursday that it was discontinuing development of a hepatitis C drug that it had acquired in a $2.5 billion deal, after nine patients in a clinical trial had to be hospitalized and one of them died. The company suspended testing of the drug on Aug. 1, after one patient in a midstage clinical trial experienced heart failure. At that time, however, there was still some question...Mon, 27 Aug 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-08-22/Gilead_drops_cicletanine_after_trial_failure.aspxSan Francisco Business Times by Ron Leuty, Reporter </p><p>Gilead Sciences Inc.'s heart and lung disease drug cicletanine failed a mid-stage trial, Dow Jones reported Tuesday, and the company is discontinuing development of the drug.</p><p>Foster City-based Gilead (NASDAQ: GILD) picked up cicletanine, aimed at pulmonary arterial hypertension patients, for an initial $10.9 million in May 2...Thu, 23 Aug 2012 12:00:00 AM GMThttp://www.washingtonpost.com/business/pfizer-and-jandj-end-testing-of-bapineuzumab-once-seen-as-breakthrough-alzheimers-treatment/2012/08/06/0ec465f2-e011-11e1-8d48-2b1243f34c85_story.html(Reuters) - Pfizer Inc and Johnson & Johnson said they were scrapping further studies of one of the most anticipated experimental Alzheimer's disease treatments after the drug failed to help patients with the memory-robbing condition in a second high-profile late stage clinical trial.Wed, 08 Aug 2012 12:00:00 AM GMThttp://www.rttnews.com/1907946/infinity-pharma-pulls-plug-on-cancer-drug-saridegib-trials-shares-plunge.aspx?type=ctInfinity Pharmaceuticals Inc. is stopping its Phase 2 trials of its experimental drug, saridegib, to treat bone and cartilage cancers, saying results have been disappointing. The drug developer said its analysis of the use of saridegib by patients with chrondrosarcoma, a rare and life-threatening cancer of the cartilage, found that results were similar to a placebo. Infinity also said it will discontinue...Tue, 19 Jun 2012 12:00:00 AM GMThttp://www.foxbusiness.com/news/2012/06/05/bioinvent-thrombogenics-cancel-development-drug-candidate/LEUVEN, <span class"xn-location">Belgium</span> and <span class"xn-location">LUND, Sweden</span>, <span class"xn-chron">June 5, 2012</span> /PRNewswire/ --</p><p>- All further development of TB-402 will be stopped</p><p>ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today the results from a Phase IIb trial comparing TB-402, a long...Tue, 05 Jun 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/05/31/chelseatherapeutics-phase2-ch-idUSL4E8GV4C020120531 CHARLOTTE, N.C., May 31, 2012 (GlobeNewswire via COMTEX) -- Chelsea Therapeutics International, Ltd. announced that a preliminary analysis of its dose-ranging exploratory Phase II trial of CH-4051, a non-metabolized antifolate, in patients with rheumatoid arthritis (RA) who experience an inadequate response to methotrexate (MTX) treatment indicates that CH-4051 did not demonstrate superior efficacy...Fri, 01 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=256684&full=1UPPSALA, Sweden--(BUSINESS WIRE)--Macrolane is a safe and well-tolerated injectable product used to augment body contour and correct soft tissue defects. Introduced in 2008, it has improved the quality of life of thousands of patients in indications ranging from HIV-related lipoatrophy to breast augmentation. A safety reporting system has been in place since launch and no safety concerns have been...Tue, 17 Apr 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/111536/sciclone-drops-oral-mucositis-candidate-scv-07.htmlSciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, has announced the results from a pre-planned interim analysis of the phase II b trial of SCV-07 in patients with oral mucositis (OM) indicate that the trial would not meet the pre-specified efficacy endpoints. After conferring with the study's independent Data Monitoring Committee (DMC), the company has decided to discontinue development...Wed, 07 Mar 2012 12:00:00 AM GMThttp://www.swedishwire.com/press-releases/12770-karo-bio-karo-bio-terminates-the-eprotirome-programKaro Bio has decided to discontinue the development program for eprotirome after an animal study demonstrated unwanted effects following long-term exposure. The company will terminate its ongoing Phase II and III studies in dyslipidemia. This termination has prompted Karo Bio to reassess its previous decision to spin off its preclinical activities, which are focused on nuclear receptors, into an autonomous...Wed, 15 Feb 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=242907&full=1December 7, 2011 -- Theratechnologies to Discontinue COPD Clinical Program and Accelerate Path to Profitability MONTREAL, QUEBEC--(Marketwire - Dec. 7, 2011) - Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) today announced that it is discontinuing its muscle wasting in COPD clinical program, downsizing and accelerating its path to profitability. The Company now aims to be profitable in 2013.</p...Wed, 07 Dec 2011 12:00:00 AM GMThttp://uk.ibtimes.com/articles/260098/20111202/sanofi-discontinues-selling-lovenox-authorized-generic.htmSanofi SA (NYSE: SNY) said in a letter sent to customers dated Nov. 30 that it has discontinued selling the Authorized Generic version of Lovenox (Enoxaparin). "We note that Sanofi's decision to discontinue the Authorized Generic was largely expected following a federal court injunction preventing sales of Amphastar's generic Enoxaparin," said Duane Nash, an analyst at Wedbush Securities. In sum, Lovenox...Mon, 05 Dec 2011 12:00:00 AM GMThttp://www.nytimes.com/2011/11/26/health/research/anti-hiv-gel-trial-is-canceled-in-africa.htmlNovember 25, 2011 -- A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants. </p><p>On Nov. 17, an independent data and safety monitoring board (DSMB) recommended...Tue, 29 Nov 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/11/22/celgene-idUSN1E7AL1WH20111122BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Srl, a subsidiary of Celgene Corporation, (NASDAQ: CELG - News) announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients...Mon, 28 Nov 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=238078&full=1STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the companys criteria. </p><p>It is a disappointment to discontinue the development program but our product candidates...Thu, 27 Oct 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=237817&full=1<div class"xn-content"><p><span class"xn-location">SAN DIEGO</span>, <span class"xn-chron">Oct. 25, 2011</span> /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients. This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants.</p><p>The top priority of Conatus...Thu, 27 Oct 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/10/07/takeda-idUST9E7KS00T20111007Takeda Pharmaceutical said on Friday it would discontinue development of insomnia drug ramelteon in Europe, after feedback on development requirements from the region's regulatory body. The drug, available as Rozerem in the United States and Japan, was once seen as a promising source of income for the Japanese firm, but sales never took off as expected because some patients found its effects were not...Mon, 10 Oct 2011 12:00:00 AM GMThttp://www.thestreet.com/story/11264777/1/sangamo-nerve-regrowth-drug-fails-key-test.html?cm_ven=GOOGLENRICHMOND, Calif., Oct. 3, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo. </p><p>"We are disappointed that this trial did not produce a better outcome in the pre-specified primary and secondary...Tue, 04 Oct 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/09/28/astellas-idUSL3E7KS17D20110928?feedType=RSS&feedName=companyNews&rpc=43Japan's Astellas Pharma said it halted the global development of the experimental anti-clotting drug darexaban maleate, or YM150, after a study raised questions about its role in treating patients with heart problems. The drugmaker said in a statement on Wednesday that it stopped development of the new oral anticoagulant amid increasing competition and after it was unable to find a partner to help...Thu, 29 Sep 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/09/22/us-immunomedics-idUSTRE78L6QA20110922MORRIS PLAINS, N.J., Sep 22, 2011 (GlobeNewswire via COMTEX) -- Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that a partial clinical hold has been placed...Mon, 26 Sep 2011 12:00:00 AM GMThttp://www.pharmatimes.com/Article/11-09-02/Eisai_terminates_long-acting_Aciphex_development.aspxWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg. </p><p>On February 1, 2011, Eisai received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application of rabeprazole sodium extended-release capsules, 50 mg. ...Tue, 06 Sep 2011 12:00:00 AM GMThttp://www.pharmalive.com/News/index.cfm?articleid=800062&categoryid=40Westport, Conn. August 24, 2011Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that Advanced BioHealing (ABH), its regenerative medicine business, has concluded its phase three pivotal trial of Dermagraft in subjects with venous leg ulcers. Following preliminary analysis of the top-line results, the decision has been made not to pursue the venous...Thu, 25 Aug 2011 12:00:00 AM GMThttp://www.businessweek.com/ap/financialnews/D9P63N503.htm <div class"xn-content"><p><span class"xn-location">CHADDS FORD, Pa.</span>, <span class"xn-chron">Aug. 17, 2011</span> /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it is terminating its research program and collaboration related to the development of axomadol. Endo licensed exclusive rights to develop and market axomadol in <span class"xn-location">the United States...Fri, 19 Aug 2011 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2011/08/04/amylin-takeda-halt-obesity-drug-development/OSAKA, Japan</span>, <span class"xn-chron">Aug. 5, 2011</span> -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin...Mon, 08 Aug 2011 12:00:00 AM GMThttp://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201107290851dowjonesdjonline000416&title=updatemerck-to-cut-up-to-13,000-jobsreports-2q-net-gainDrugmaker Merck & Co.'s second-quarter profit nearly tripled from a year ago, when about $2 billion in charges hurt results. Merck also said Friday that it will cut up to 11,830 jobs. The maker of asthma and allergy drug Singulair and Type 2 diabetes pill Januvia said Friday that it's starting another restructuring progam, which will eliminate 12 percent to 13 percent of jobs by 2015. That would amount...Thu, 04 Aug 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20110718_1July 18, 2011 -- Beijing BeiLu Pharmaceutical decided to end its agomelatine development project. The company said the SFDA refused to authorize a clinical trial of agomelatine, an antidepressant drug, saying the IND filing did not prove the drug was effective. BeiLu explained that a new application for a clinical trial would take three years, which it feels would cause the company to miss the most...Tue, 19 Jul 2011 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/lack-of-partner-prompts-genmab-to-sideline-late-stage-cancer-antibody/81245346/Genmab A/S (Copenhagen:GEN) announced today it will wind down the zalutumumab clinical program. After an extensive search during the first half of the year, the company has not found a satisfactory partnership to take zalutumumab forward in the current climate. As part of the company's disciplined approach and commitment to controlling costs, Genmab will wind down the zalutumumab program. Genmab will...Tue, 28 Jun 2011 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/diamyd-discontinues-u-s-phase-iii-trial-with-type-i-diabetes-product/81245338/STOCKHOLM, Jun 23, 2011 (BUSINESS WIRE) -- Regulatory News: Diamyd Medical AB (sto:DIAMB) reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd(R) and to initiate closure of the study. </p><p>Following consultation with the US Food and Drug Administration (FDA), Diamyd Medical has decided to suspend dosing in its US Phase III study...Fri, 24 Jun 2011 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/enzon-ditches-development-of-peg-sn38-for-mcrc-but-continues-development-for-other-cancers/81245179/PISCATAWAY, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN - News) today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study. Enzon continues to enroll studies for the Companys other PEG-SN...Thu, 19 May 2011 12:00:00 AM GMThttp://www.kktv.com/home/headlines/Drugmakers_Eliminate_Infant_Drops_of_Key_Medicine_121293999.html?storySection=commentsJohnson & Johnson and other makers of cold and fever medications said Wednesday that they will discontinue infant drops of medicines containing acetaminophen in an effort to avoid confusion that can lead to dangerous overdoses. The industry association for over-the-counter medicine companies said its members will begin phasing out the liquid drops later this year. After the transition is complete...Thu, 05 May 2011 12:00:00 AM GMThttp://www.veterinarypracticenews.com/vet-breaking-news/2011/04/18/study-links-promeris-to-pemphigus-foliaceus-pfizer-stopping-its-production.aspxVeterinary Practice News -- A recent groundbreaking study of clinical, histological and immunological data of 22 cases of Pemphigus foliaceus, or PF, shows evidence that it can occur as an adverse drug reaction to the canine flea and tick preventive ProMeris.</p><p>PF is the most common spontaneously occurring autoimmune skin disease of dogs and typically displays as lesions on the face, nasal...Mon, 25 Apr 2011 12:00:00 AM GMThttp://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=1598782MECHELEN, BELGIUM--(Marketwire - 04/15/11) - Galapagos NV (Brussels:GLPG - News) announced today that it will discontinue its Phase II clinical trial for GLPG0259 in rheumatoid arthritis. This decision is based on the outcome of a planned interim analysis which did not support the continuation of GLPG0259's development for rheumatoid arthritis.</p><p>An Interim Review Committee of key opinion leaders...Fri, 15 Apr 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=216596&full=1PALO ALTO, Calif., April 8, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced that it has discontinued its Phase Ib clinical trial in neuronal ceroid lipofuscinosis (NCL, also referred to as Batten disease), a rare and fatal neurodegenerative disorder in children, due to lack of patient accrual. In 2009, the Company completed a Phase I safety trial of its HuCNS-SC(R) human...Fri, 08 Apr 2011 12:00:00 AM GMThttp://www.pharmalot.com/2011/03/mon-dieu-france-rejects-astrazeneca-bloodthinner/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot%29Pharmalot -- Just three months after the FDA rejected the new Brilinta bloodthinner from AstraZeneca, France is now reportedly giving the drugmaker a hard time as well. Even though the European Medicines Agency already endorsed the treatment, the HAS health technology assessment agency in France has decided the med has an unfavorable risk/benefit profile, which puts a halt to final pricing talks and...Thu, 24 Mar 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/03/07/astrazeenca-skyepharma-idUSLDE72608V20110307LONDON, March 7 (Reuters) - AstraZeneca (AZN.L) is ending production of the pressurised metered dose inhaler version of its asthma drug Pulmicort, due to technical problems, in a move that will hit its technology partner SkyePharma (SKP.L).Mon, 07 Mar 2011 12:00:00 AM GMThttp://www.scripintelligence.com/researchdevelopment/Innate-drops-IPH-1101-development-312119Scrip Intelligence -- The French firm Innate Pharma has stopped its development programme for IPH 1101, an agonist of gamma delta T cells, which had previously shown a possible clinical benefit in folicullar lymphoma and an anti-viral effect against type C viral hepatitis. Fri, 04 Mar 2011 12:00:00 AM GMThttp://www.inpharm.com/news/149639/pfizer-drops-15-pipeline-projectsNEW YORK--(BUSINESS WIRE)--Feb 28, 2011 - Pfizer Inc. today provided an update to its development pipeline, available at www.pfizer.com/pipeline. The updated pipeline includes an overview of the company's research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action.<p></p>The company has redesigned the format of the...Tue, 01 Mar 2011 12:00:00 AM GMT